Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 6 studies | 27% ± 9% | |
| neuron | 4 studies | 24% ± 6% | |
| GABAergic neuron | 4 studies | 42% ± 16% | |
| glutamatergic neuron | 4 studies | 44% ± 16% | |
| astrocyte | 4 studies | 27% ± 12% | |
| microglial cell | 3 studies | 20% ± 1% | |
| epithelial cell | 3 studies | 21% ± 2% | |
| oligodendrocyte precursor cell | 3 studies | 22% ± 5% | |
| endothelial cell of lymphatic vessel | 3 studies | 19% ± 2% | |
| interneuron | 3 studies | 44% ± 21% | |
| oligodendrocyte | 3 studies | 25% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 5 studies | 34% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| uterus | 100% | 1061.60 | 170 / 170 | 100% | 25.56 | 457 / 459 |
| ovary | 100% | 566.08 | 180 / 180 | 100% | 25.11 | 428 / 430 |
| skin | 100% | 1321.43 | 1809 / 1809 | 99% | 16.53 | 467 / 472 |
| breast | 100% | 779.08 | 459 / 459 | 99% | 14.69 | 1106 / 1118 |
| brain | 99% | 536.78 | 2617 / 2642 | 99% | 15.05 | 701 / 705 |
| bladder | 100% | 812.67 | 21 / 21 | 98% | 15.67 | 496 / 504 |
| esophagus | 100% | 941.22 | 1445 / 1445 | 98% | 21.77 | 180 / 183 |
| lung | 100% | 707.51 | 576 / 578 | 99% | 25.30 | 1138 / 1155 |
| stomach | 99% | 475.35 | 355 / 359 | 99% | 11.98 | 283 / 286 |
| intestine | 100% | 735.99 | 966 / 966 | 97% | 11.13 | 513 / 527 |
| prostate | 100% | 748.11 | 245 / 245 | 97% | 9.63 | 487 / 502 |
| kidney | 100% | 523.38 | 89 / 89 | 94% | 10.98 | 844 / 901 |
| thymus | 100% | 640.12 | 653 / 653 | 93% | 8.28 | 561 / 605 |
| adrenal gland | 100% | 571.53 | 258 / 258 | 85% | 7.29 | 196 / 230 |
| pancreas | 85% | 212.38 | 280 / 328 | 97% | 12.20 | 172 / 178 |
| adipose | 100% | 873.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 715.55 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 34.48 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 15.18 | 1 / 1 |
| blood vessel | 100% | 657.03 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 96% | 344.06 | 827 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 91% | 7.72 | 73 / 80 |
| peripheral blood | 91% | 418.02 | 845 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 83% | 8.30 | 24 / 29 |
| liver | 46% | 91.30 | 105 / 226 | 31% | 2.65 | 126 / 406 |
| muscle | 58% | 113.30 | 467 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0016266 | Biological process | O-glycan processing |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0030145 | Molecular function | manganese ion binding |
| GO_0140560 | Molecular function | xylosyl alpha-1,3-xylosyltransferase activity |
| GO_0000287 | Molecular function | magnesium ion binding |
| GO_0035252 | Molecular function | UDP-xylosyltransferase activity |
| Gene name | XXYLT1 |
| Protein name | Xyloside xylosyltransferase 1 (EC 2.4.2.62) (UDP-xylose:alpha-xyloside alpha-1,3-xylosyltransferase) Xyloside xylosyltransferase 1 |
| Synonyms | PSEC0251 C3orf21 |
| Description | FUNCTION: Alpha-1,3-xylosyltransferase, which elongates the O-linked xylose-glucose disaccharide attached to EGF-like repeats in the extracellular domain of target proteins by catalyzing the addition of the second xylose . Known targets include Notch proteins and coagulation factors, such as F9 . . |
| Accessions | ENST00000356740.5 [Q8NBI6-3] Q8NBI6 ENST00000429994.5 ENST00000455281.1 H7C2F4 A0A140T9D0 ENST00000437101.5 [Q8NBI6-2] ENST00000310380.11 [Q8NBI6-1] ENST00000418940.5 F8WEN6 |
